{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-044593","form_type":"8-K","ticker":"CGEM","cik":"0001789972","company_name":"Cullinan Therapeutics, Inc.","filed_at":"2024-04-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.128983+00:00","generated_at":"2026-06-03T22:21:50.685115+00:00","sec_items":["1.01","3.02","5.03","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Cullinan raises $280M, pivots to autoimmune with promising CLN-978 data; cash runway into 2028","bullets":["$280M private placement at $19/share; pre-funded warrants $18.999; extends cash runway into 2028.","Strategic pivot to autoimmune diseases; first indication systemic lupus erythematosus (SLE); IND planned Q3 2024.","CLN-978 Phase 1 B-NHL data: 1 complete response, rapid B cell depletion, low-grade CRS, no ICANS.","Name change to Cullinan Therapeutics (Nasdaq: CGEM); reflects expanded focus beyond oncology.","Enrollment in B-NHL study discontinued to focus on autoimmune development."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-044593","json":"https://secwatch.observer/filing/0000950170-24-044593.json","markdown":"https://secwatch.observer/filing/0000950170-24-044593.md","text":"https://secwatch.observer/filing/0000950170-24-044593.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789972/000095017024044593/0000950170-24-044593-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789972/000095017024044593/cgem-20240415.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T22:21:50.685115+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"86ab9116b16ca97713d7a702ad556c56b8a38bdf","claim":"Cullinan Therapeutics, Inc.: Amended certificate of incorporation to change company name from Cullinan Oncology, Inc. to Cullinan Therapeutics, Inc (effective 2024-04-15).","evidence_excerpt":"Effective as of 9:47 A.M., Eastern Time on April 15, 2024, the Company amended its Second Amended and Restated Certificate of Incorporation, as amended (the “ Certificate of Incorporation ”), to effect a change of the Company’s name from “Cullinan Oncology, Inc.” to “Cullinan Therapeutics, Inc.” (the “ Name Change ”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1789972/000095017024044593/0000950170-24-044593-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2024-04-15"}],"fact_type":"governance_change"},{"claim_id":"9caf408d55111302b41a15823a7ee07c07dc9ed8","claim":"Cullinan Therapeutics, Inc.: Amended and restated bylaws solely to reflect the name change (effective 2024-04-15).","evidence_excerpt":"the Board also approved an amendment and restatement of the Company’s Second Amended and Restated Bylaws solely to reflect the Name Change (as amended and restated, the “ Third Amended and Restated Bylaws ”) effective as of April 15, 2024.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1789972/000095017024044593/0000950170-24-044593-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2024-04-15"}],"fact_type":"governance_change"},{"claim_id":"5837751a3cb2a5fc83a0bc3cc6e72f4753da8acc","claim":"Cullinan Therapeutics, Inc. entered into Stock Purchase Agreement with certain institutional accredited investors valued at $280M gross proceeds for sale of 14,421,070 shares at $19.00/share and 315,790 pre-funded warrants a (effective 2024-04-15).","evidence_excerpt":"On April 15, 2024, Cullinan Therapeutics, Inc. (formerly known as Cullinan Oncology, Inc.) (the “ Company ”) entered into a Stock Purchase Agreement (the “ Purchase Agreement ”) for a private placement (the “ Private Placement ”) with certain institutional accredited investors named therein (each, a “ Purchaser ” and collectively, the “ Purchasers ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1789972/000095017024044593/0000950170-24-044593-index.htm","confidence":0.99,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional accredited investors"},{"label":"Value","value":"$280M gross proceeds for sale of 14,421,070 shares at $19.00/share and 315,790 pre-funded warrants a"},{"label":"Effective","value":"2024-04-15"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}